Abstract
Cytochrome P-450 1A1 is an important enzyme in the first phase of the metabolism of some carcinogens such as polycyclic aromatic hydrocarbons (PAHs), as well as estrogen. The present study evaluates the existence of CYP1A1 polymorphism in a number of breast cancer samples. One hundred breast cancer patients and the same number of healthy controls were analyzed for the A2455G polymorphism of cytochrome P-450 1A1 by the polymerase chain reaction-restriction fragment length polymorphism technique. Frequency of heterozygote genotype (A/G) indicated significant increase in case group (17%) compared to control group (7%) (OR=2.7; 95% CI=1.07-6.89; P-value=0.03). The related result of (A/A) genotype showed significantly decreased risk of breast cancer (OR=0.34; P-value=0.01). Higher frequency of heterozygotes was mainly observed among premenopausal breast cancer patients. Our results suggest that the CYP1A1 polymorphism may be useful for predicting breast cancer risk in our study population.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
